Table 1.
Adenoviral vector vaccines against pathogens
| Serotype of Ad | Pathogens | Status | NCT no. |
|---|---|---|---|
| Ad5 | SARS-CoV-2 | phase I | NCT05526183 |
| Ad5 and ChAd68 | SARS-CoV-2 | phase 1 | NCT05094609 |
| AdCLD (Chimeric 5/35) | SARS-CoV-2 | active | NCT04666012 |
| ChAdOx1 | SARS-CoV-2 | phase 2 | NCT05049226 |
| ChAdV68 | SARS-CoV-2 | phase 1 | NCT04776317 |
| Ad 4 | HIV | phase 1 | NCT02771730 |
| Ad5 or Ad35 | HIV | phase 1 | NCT00472719 |
| Ad26 | HIV | phase 1 | NCT00618605 |
| AdC6 and AdC7 | HIV | phase 1 | NCT05182125 |
| Ad3 | Ebola | phase 1 | NCT04041570 |
| Ad5 | Ebola | phase I/II | NCT04840992 |
| Ad26 | Ebola | phase 3 | NCT02509494 |
| Ad26 | hemorrhagic fever, Ebola | phase 2 | NCT02564523 |
| Unknown | influenza (H1N1) | phase 2 | NCT02918006 |
| Ad4 | H5N1 | phase 1 | NCT01443936 |
| Unknown | norovirus | phase 1 | NCT03125473 |
| Unknown | norovirus | phase 1 | NCT02868073 |
| ChAd3 | Marburg virus disease | phase 2 | NCT05817422 |
| ChAd63 | malaria Plasmodium vivax | phase Ia | NCT01816113 |
| Ad35 | malaria | phase 2 | NCT01366534 |
| Ad5 | malaria | phase 2 | NCT00870987 |
| ChAdOx2 | Crohn disease, Mycobacterium avium subspecies paratuberculosis | phase 1 | NCT03027193 |
| ChAdOx1 | MERS | phase 1 | NCT03399578 |
| Ad26 | RSV | phase 2 | NCT03303625 |
| Ad35 | Plasmodium falciparum | phase 1 | NCT00371189 |
| ChAd155- | hepatitis B | phase 2 | NCT03866187 |
| ChAd3 | hepatitis C | phase 1 | NCT03688061 |
| AdCh3 and Ad6 | hepatitis C | phase 1 | NCT01094873 |
| ChAdOx1 | chikungunya fever | phase 1 | NCT03590392 |
| Ad4 | anthrax infection | phase 1 | NCT01979406 |